Abuse deterrent opioids

References 

1. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain. 1994;59:201–208
   • Abstract
   • Full-Text PDF (1170 KB)
   • CrossRef
2. Manchikanti L. Prescription drug abuse: What is being done to address this new drug epidemic? (Testimony before the Subcommittee on Criminal Justice. Drug Policy and Human Resources). Pain Physician. 2006;9:287-231
3. Fleming A, Noonan P, Schiller M. Tamper-resistant properties and bioavailability of a novel, multiparticulate, extended-release formulation of oxycodone for the treatment of moderate to severe pain. Pain Med. 2010;11:317;(abstract)
4. Friedmann N, Butera P, Klutzaritz D, et al: Abuse-resistant, longacting oxycodone treats chronic pain in a large phase III study: Presented at the 12Th World Congress on Pain, Glasgow, Scotland, 2008 (abstract)
5. Parasrampuria D, Schodel K, Schuller R, et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol. 2007;47:1476
   • CrossRef
6. Katz N, Sun S, Fow L, et al. Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis. J Pain. 2008;9:41
   • Full Text
   • Full-Text PDF (43 KB)
   • CrossRef
7. Johnson F, Jones JB, Stauffer J: Relative bioavailability of naltrexone from crushed ALO-01 (an investigational, abuse-deterrent, extended-release morphine sulfate formulation with sequestered naltrexone hydrochloride) to a naltrexone oral solution, in Poster Presentation at American Pain Society's 27th Annual Scientific Meeting, abstract:236, 2008
8. Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain. 2006;7:937–946
   • Abstract
   • Full Text
   • Full-Text PDF (185 KB)
   • CrossRef
9. Largent-Milnes TM, Guo W, Wang HY, et al. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor Gs coupling. J Pain. 2008;9:700–713
   • Abstract
   • Full Text
   • Full-Text PDF (1056 KB)
   • CrossRef
10. Acura, Pharmaceuticals, Inc.. A comparison of the abuse resistant properties of three commercially available opioid tablets versus opioid tablets formulated with Aversion technology. http://acurapharm.com2007;